# Biosyntia

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/biosyntia-aps

- Industry: Biotechnology
- Headquarters: Copenhagen, Denmark
- Website: www.biosyntia.com
- Total disclosed funding: $22M
- Latest round: Series B (Sep 30, 2022)
- Investors on record: 6

## About

Biosyntia ApS focuses on developing innovative nutritional products using natural ingredients to enhance personal care and health solutions, catering primarily to health-conscious consumers.Founded in 2012 in Copenhagen, Denmark, Biosyntia ApS specializes in the development of natural nutritional products. The company has successfully executed five deals, with its most recent funding round being a Series B, raising EUR 6.000 mn on June 1, 2024, from investors including Praesidium and Vaekstfonden. The founders, Andreas Laustsen-Kiel, Hans Genee, and Morten Sommer, have collectively contributed their expertise in biotechnology and product innovation to establish the company.Biosyntia ApS specializes in developing innovative nutritional products that leverage natural ingredients to address specific health needs. Their core offerings include BioB7 ForskoPro, which supports hair health, and CitriVive, alongside the skin health formulation eraGlow. These products utilize unique technology to provide natural alternatives for consumers seeking effective solutions in personal care and nutritional support. The company targets a range of customers, including health-conscious individuals and beauty product retailers, primarily focusing on markets in Europe, North America, and select areas in Asia. Biosyntia’s products are designed to meet the growing demand for clean-label, effective health solutions, positioning them within the burgeoning wellness and personal care sectors.Biosyntia ApS generates revenue through a combination of direct-to-consumer sales and partnerships with retailers and wholesalers. The company's transaction structure is designed to facilitate smooth engagement with its client base, which includes both individual consumers and commercial partners. Revenue streams are derived from sales of their flagship products, such as BioB7 ForskoPro and CitriVive, focusing on subscription models or bulk purchasing agreements for larger retailers. Pricing strategies are aligned with market expectations, providing competitive rates that reflect the quality and efficacy of their products. In the most recent year, the company's EBITDA stood at EUR -4,964,809.50.Biosyntia ApS plans to launch new products in the upcoming year to expand its product lineup, specifically targeting launches in late 2024. The company aims to penetrate new markets in Asia and North America, with efforts to establish a stronger presence by 2025. The recent Series B funding, which raised EUR 6.000 mn, will be utilized to support these product launches as well as to enhance marketing efforts and operational capacity to reach the targeted geographic expansion.

## Funding rounds

- Series B, Sep 30, 2022, $5.9M — Vaekstfonden, Praesidium
- Series B, Jul 6, 2022, $12M — Sofinnova Partners, Novo Holdings, ECBF
- Series A, May 23, 2018, $4.7M — Sofinnova Partners, Novo Seeds

## Investors

- Sofinnova Partners (https://capitalatlas.ai/funds/sofinnova-partners) — Series A, Series B
- Novo Seeds — Series A
- Novo Holdings — Series B
- ECBF (https://capitalatlas.ai/funds/ecbf) — Series B
- Vaekstfonden (https://capitalatlas.ai/funds/vaekstfonden) — Series B
- Praesidium (https://capitalatlas.ai/funds/praesidium) — Series B